Cell cycle regulation of human pancreatic cancer by tamoxifen

Annals of Surgical Oncology

Volumn 5, Issue 4, 1998, Pages 342-349

  Robinson, Emily K ^a   Grau, Ana M ^a   Evans, Douglas B ^a   Smid, Christine M ^a   Chiao, Paul J ^a   Abbruzzese, James L ^a   Grimm, Elizabeth A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Apoptosis; Cell cycle arrest; Cell lines; P21(waft)

Indexed keywords

TAMOXIFEN;

APOPTOSIS; ARTICLE; CANCER HORMONE THERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; HUMAN; HUMAN CELL; METASTASIS; PANCREAS CANCER; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; CELL CYCLE; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMANS; PANCREATIC NEOPLASMS; RNA, MESSENGER; RNA, NEOPLASM; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0031778287     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02303498     Document Type: Article

References (28)

1. Pousette A, Carlstrom K, Skoldefors H, et al. Purification and partial characterization of a 17β-estradiol binding macromolecule in the human pancreas. Cancer Res 1982;42:633-7.
2. Benez C, Hollander C, Miller B. Endocrine-responsive pancreatic carcinoma: steroid binding and cytotoxicity in human tumor cell lines. Cancer Res 1986;46:2276-81.
3. Theve NO, Pousette A, Carlstrom K. Adenocarcinoma of the pancreas - a hormone sensitive tumor? A preliminary report of Nolvadex treatment. Clin Oncol 1983;9:193-7.
4. Tonnesen K, Kamp-Jensen M. Antiestrogen therapy in pancreatic carcinoma: a preliminary report. Eur J Surg Oncol 1986;12:69-70.
5. Wong A, Chan A. Survival benefit of tamoxifen therapy in adenocarcinoma of the pancreas. A case-control study. Cancer 1993;71: 2200-3.
6. Taylor OM, Benson EA, McMahon MJ. Clinical trial of tamoxifen in patients with irresectable pancreatic adenocarcinoma. Br J Surg 1993;80:384-6.
7. Keating JJ, Johnson PJ, Cochrane AMG, et al. A prospective randomised controlled trial of tamoxifen and cyproterone acetate in pancreatic carcinoma. Br J Cancer 1989;60:789-92.
8. Bakkevold KE, Pettersen A, Arnesjo B, Espehaug B. Tamoxifen therapy in unresectable adenocarcinoma of the pancreas and the papilla of Vater. Br J Surg 1990;77:25-30.
9. Woods CM, Zhu J, McQueney PA, Bollag D, Lazarides E. Taxolinduced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med 1995;1:505-26.
10. Danesi R, Figg WD, Reed E, Myers CE. Paclitaxel (taxol) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cells. Mol Pharm 1995;47:1106-11.
11. Jordon MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 1996;56:816-25.
12. Chomezynski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
13. Sambrook J, Fritsch E, Maniatis T. Synthesis of uniformly labeled DNA probes using random oligonucleotide primers. In: Nolan C, ed. Molecular Cloning. A Laboratory Manual. Cold Spring Harbor, NY: Laboratory Press, 1989;2:10.13-5.
14. Sherr CJ. G1 phase progression: cycling on cue. Cell 1994;79: 551-5.
15. McClay EF, Jones JA, Winski PJ, Albright KD, Christen RD, Howell SB. Determinants of tamoxifen sensitivity control the nature of the synergistic interaction between tamoxifen and cisplatin. Cancer Res 1996;56:3993-7.
16. Perry RR, Kang Y, Greaves B. Effects of tamoxifen on growth and apoptosis of estrogen-dependent and independent human breast cancer cells. Ann Surg Oncol 1995;2:238-45.
17. Michieli P, Chedid M, Lin D, Pierce JH, Mercer EW, Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 1994;54:3391-5.
18. WAF1/CIP1 expression in human breast carcinoma cells. Cancer Res 1996;56:5055-62.
19. Ruggeeri B, Zhang S-Y, Caamano J, DiRado M, Flynn SD, Klein-Szanto AJP. Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in p53 and Rb-I tumor-suppressor genes. Oncogene 1992;7:1503-11.
20. Pan G, Ying W, Vickers SM, Phillips JO, McDonald JM. Involvement of the Fas/APO-1(CD95) in tamoxifen-induced apoptosis in cholangiocarcinoma. Proceedings of the American Association of Cancer Research 1997;38:625.
21. Reddel RR, Murphy LC, Hall RE, Sutherland RL. Differential sensitivity of human breast cancer cell lines to the growth-inhibitory effects of tamoxifen. Cancer Res 1985;45:1525-31.
22. Greenway B, Iqbal M, Johnson P, Williams R. Oestrogen receptor proteins in malignant and fetal pancreas. Br Med J 1981;283: 751-3.
23. Taylor O, Teasdale P, Cowen P, McMahon M, Benson E. Classical oestrogen receptor is not detectable in pancreatic adenocarcinoma. Br J Cancer 1992;66:503-6.
24. 3H]estradiol to protein in the cytosol fraction of rat pancreas. Proc Natl Acad Sci USA 1981;78:5648-51.
25. Kuramoto M, Yamashita J-I, Ogawa M. Tissue-type plasminogen activator predicts endocrine responsiveness of human pancreatic carcinoma cells. Cancer 1995;75:1263-72.
26. McClay E, McClay M-E, Jones J, Winski P, Christen R, Howell S, Hall PA. Phase I study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma. Cancer 1997;79:1037-43.
27. Stuart N, Philip P, Harris A, et al. High-dose tamoxifen as an effector of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines. Br J Cancer 1992;66:833-9.
28. 14C labelled tamoxifen in spayed female mice. Acta Pharmacologica et Toxicologica 1982; 50:161-8.